Swedish biotechnology company Cantargia AB (STO:CANTA) said on Wednesday that it has been granted a new patent by the United States Patent and Trademark Office covering its antibody nadunolimab.

The patent, US 12,398,213, protects treatment methods combining nadunolimab with chemotherapy and/or immunotherapy and is valid until 2035, excluding any extensions.

Nadunolimab, an anti-IL1RAP antibody wholly owned by Cantargia, is in clinical development for both solid and haematological tumours. The company's lead indication for nadunolimab is pancreatic ductal adenocarcinoma (PDAC) in combination with chemotherapy, which falls within the scope of the new patent.

In June 2025, the US FDA granted nadunolimab Fast Track Designation for patients with metastatic PDAC expressing high IL1RAP levels. This designation enables more frequent FDA interactions and potential eligibility for Accelerated Approval and Priority Review.

Cantargia holds a broad intellectual property portfolio, with more than 100 patents globally covering IL1RAP-targeting antibodies for cancer therapy and diagnostics in markets including the US, Europe, Japan and China.